Zealand Pharma A/S (Zealand Pharma A/S) Current Deferred Revenue : $0.00 Mil (As of Mar. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Zealand Pharma A/S Current Deferred Revenue?

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Zealand Pharma A/S's current deferred revenue for the quarter that ended in Mar. 2024 was $0.00 Mil.

Zealand Pharma A/S Current Deferred Revenue Historical Data

The historical data trend for Zealand Pharma A/S's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zealand Pharma A/S Current Deferred Revenue Chart

Zealand Pharma A/S Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Current Deferred Revenue

Get a 7-Day Free Trial

8.37

8.70

8.06

Zealand Pharma A/S Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Current Deferred Revenue	Get a 7-Day Free Trial															-	-	-	-	-

Zealand Pharma A/S Current Deferred Revenue Related Terms

Thank you for viewing the detailed overview of Zealand Pharma A/S's Current Deferred Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Zealand Pharma A/S (Zealand Pharma A/S) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zealand Pharma A/S (OTCPK:ZLDPF) » Definitions » Current Deferred Revenue

Comparable Companies

Traded in Other Exchanges

ZEALc:UK 0NZU:UK ZEAL:Denmark 22Z:Germany

Address

Sydmarken 11, Soborg, DNK, DK-2860

Website

https://www.zealandpharma.com

Zealand Pharma A/S is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.